CORT Corcept Therapeutics Inc.
Health Care, filed as CORCEPT THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab
- 1 exit
In 2026 Q2 David Witzke sold out of Corcept Therapeutics.
Who owns CORT
Sorted by value, long equity only, as of 2026 Q2. Exits show their last held size.
| History | |||||
|---|---|---|---|---|---|
| David Witzke, Avidity Partners Management exited 2026 Q2 Last 2026 Q1 | Exit −0.32% | 30,000 | $1.4M | History |
Insider trades
Open-market buys and sales by CORT's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $3.3M bought by 1 insider
- $7M sold by 5 insiders outside a trading plan
- $94.2M sold by 8 insiders under 10b5-1 plans
-
James N Wilson DirectorPlanned sale$1.1M 10,000 shares at $114.81 0.9% of stakeTraded Oct 15 Filed Oct 16
-
Roberto Wandenkolk Vieira President, OncologyPlanned sale$967K 8,333 shares at $116.10 68% of stakeTraded Oct 2 Filed Oct 5
-
Joseph Douglas Lyon See RemarksPlanned sale$1.2M 10,000 shares at $116.07 64% of stakeTraded Oct 1–2 Filed Oct 5
-
Sean Maduck See RemarksPlanned sale$2.9M 25,000 shares at $116.26 72% of stakeTraded Oct 1–2 Filed Oct 5
-
Roberto Wandenkolk Vieira President, OncologyPlanned sale$30K 296 shares at $100.82 7% of stakeTraded Sep 16 Filed Sep 18
-
Joseph Douglas Lyon See RemarksPlanned sale$1.1M 10,000 shares at $113.49 64% of stakeTraded Sep 14 Filed Sep 16
-
James N Wilson DirectorPlanned sale$1.1M 10,000 shares at $110.69 0.9% of stakeTraded Sep 15 Filed Sep 16
-
Sean Maduck See RemarksPlanned sale$2.9M 25,000 shares at $114.43 72% of stakeTraded Sep 1 Filed Sep 3
-
Roberto Wandenkolk Vieira President, OncologyPlanned sale$6.5M 58,333 shares at $110.76 93% of stakeTraded Sep 2 Filed Sep 3
-
Kimberly Park DirectorSale$3.3M 26,685 shares at $122.55 100% of stakeTraded Aug 26 Filed Aug 28
-
Sean Maduck See RemarksPlanned sale$3.9M 30,955 shares at $125.58 76% of stakeTraded Aug 25 Filed Aug 27
-
David L Mahoney DirectorPlanned sale$12.3M 103,606 shares at $118.25 8.4% of stakeTraded Aug 18 Filed Aug 20
-
Sean Maduck See RemarksPlanned sale$419K 3,664 shares at $114.49 27% of stakeTraded Aug 14 Filed Aug 18
-
James N Wilson DirectorPlanned sale$1.1M 10,000 shares at $111.43 0.9% of stakeTraded Aug 14 Filed Aug 18
-
Gary Charles Robb Chief Business OfficerSale$1.2M 10,000 shares at $116.26 20% of stakeTraded Aug 17 Filed Aug 18
Also filed in the last 12 months, not counted as buying or selling: 50 option exercises, 42 stock grants, 30 gifts, 23 share withholdings for taxes, and 9 other transactions.
SEC filings
Recent issuer filings from EDGAR, 5 shown.
Financials
US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.
Income statement
Balance sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total current assets | $458.64M | $471.6M | $485.46M |
| Total non-current assets * | $162.88M | $368.95M | $351.19M |
| Total assets | $621.52M | $840.55M | $836.65M |
| Total current liabilities | $104.5M | $140.77M | $166.08M |
| Total non-current liabilities * | $10.31M | $20.19M | $22.76M |
| Total equity | $506.7M | $679.59M | $647.8M |
Ownership over time
13Fs that reported it each quarter. Click a bar for that quarter’s holders.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon